<DOC>
	<DOCNO>NCT00136084</DOCNO>
	<brief_summary>The purpose study compare effectiveness two multi-agent chemotherapy regimens use different dosage cytarabine eliminate detectable leukemia .</brief_summary>
	<brief_title>Treatment Patients With Newly Diagnosed Acute Myeloid Leukemia Myelodysplasia</brief_title>
	<detailed_description>The study compare effectiveness two dos cytarabine combine set dos daunomycin etoposide initial course chemotherapy eliminate minimal residual disease . Subsequent therapy tailor accord cytogenetic risk feature , assessment minimal residual disease , availability suitable donor bone marrow transplant . Patients high risk disease feature give intense therapy . For high risk group , transplant give patient suitable donor . Secondary objective include : - To assess prognostic value biological marker childhood Acute Myeloid leukemia ( AML ) . - To compare amount leukemia cell blood bone marrow study minimal residual disease ( MRD ) . - To relate non-invasive cardiac evaluation health-related quality life AML patient treat cardiotoxic therapy follow therapy . Detailed Description Treatment Plan Induction I Patients randomly assign receive induction therapy consist daunomycin , etoposide , high-dose low-dose cytarabine . High-Dose Cytarabine ( HDAC ) arm : Cytarabine 3 gm/m2 IV day 1 , 3 , 5 Daunomycin 50 mg/m2 IV day 2 , 4 , 6 Etoposide 100 mg/m2 IV day 2-6 Low-Dose Cytarabine ( LDAC ) arm : Cytarabine 100 mg/m2 IV day 1-10 ( 20 dos ) Daunomycin 50 mg/m2 IV day 2 , 4 , 6 Etoposide 100 mg/m2 IV day 2-6 Induction II Patients &lt; 1 % MRD Induction I receive daunomycin , cytarabine , etoposide ( ADE ) : Daunomycin 50 mg/m2 IV day 1 , 3 , 5 Cytarabine 100 mg/m2 IV 1-8 ( 16 dos ) Etoposide 100 mg/m2 IV day 1-5 Patients â‰¥ 1 % MRD Induction I receive daunomycin , cytarabine , etoposide ( ADE ) + gemtuzumab ozogamicin : Daunomycin 50 mg/m2 IV day 1 , 3 , 5 Cytarabine 100 mg/m2IV day 1-8 ( 16 dos ) Etoposide : 100 mg/m2 IV day 1-5 Gemtuzumab ozogamicin ( GO ) 3 mg/m2 IV day 1 . Consolidation I ( Chemotherapy course 3 ) The chemotherapy administer course 3 base participant 's response cytogenetic/morphologic subgroup MRD+ patient ( except receive ADE + GO ) Gemtuzumab ozogamicin 6 mg/m2 IV day 1 MRD+ patient No response ( NR ) induction I These patient proceed Stem Cell Transplant ( SCT ) soon possible . In case SCT delay ( e.g. , search unrelated donor ) , patient receive chemotherapy accord cytogenetic morphologic subtype time SCT . MRD- patient ( i.e. , patient MRD- ADE GO ) receive risk-based intensification ( RBI ) ( 9 ; 11 ) inv ( 16 ) Cytarabine 500 mg/m2/day continuous infusion 120 hour Cladribine ( 2CDA ) 9 mg/m2 : IV 30 minute daily 5 day Amend 8 M4/M5 without ( 9 ; 11 ) inv ( 16 ) : CE Cytarabine 3 gm/m2 IV q12h x 6 dos ( day 1-3 ) continuous infusion 3 hour . Etoposide 125 mg/m2 IV day 2-5 continuous infusion least one hour ( 8 ; 21 ) others : HAM Cytarabine 3 g/m2 IV x 6 dos ( day 1-3 ) Mitoxantrone 10 mg/m2 IV day 3-4 Standard-risk patient match related donor high-risk patient proceed stem cell transplant per institutional practice Consolidation II ( Chemotherapy course 4 ) : Cytarabine 3 gm/m2 IV q12 hour day 1 , 2 , 8 , 9 ( 8 dos ) L-Asparaginase 6000 Units/m2 IM 3 hour 4th 8th dos cytarabine Consolidation III ( Chemotherapy course 5 ) Mitoxantrone 10 mg/m2 IV day 1-3 Cytarabine 1 gm/m2 IV 2 hour q12 hour day 1-3 ( 6 dos ) Patients first remission eligible enrol St. Jude protocols NKAML protocol receive Natural Killer ( NK ) cell therapy instead Consolidation III Consolidation III . At discretion primary physician , patient offer option enrol NKAML . Some patient biphenotypic leukemia respond poorly AML-directed therapy , respond quite well lymphoid-directed therapy . Patients marker response induction I fail achieve complete response ( CR ) induction II therefore receive lymphoid direct induction therapy . Other biphenotypic patient continue receive AML-directed therapy describe All patient undergo lumbar puncture receive age-appropriate dose intrathecal ( IT ) cytarabine time diagnosis . Patients without Central Nervous System disease ( CNS ) ( i.e. , less 5 leukocyte per microliter CSF ( colony-stimulating factor ) receive one dose intrathecal ( IT ) methotrexate , hydrocortisone , cytarabine ( MHA ) course chemotherapy begin induction II . Patients overt CNS leukemia ( equal 5 leukocyte per l microliter CSF presence leukemic blast cell CSF cytospin ) receive weekly IT MHA therapy begin 1 week initial dose IT cytarabine continue CSF free blast cell ( minimum number dos , 4 ) . These patient receive 4 additional dos intrathecal therapy methotrexate , hydrocortisone , cytarabine ( IT MHA ) ( minimum total number dos , 8 ) approximately 1-month interval ( generally give subsequent course chemotherapy ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia immunophenotyping , morphology , cytochemical staining ; myelodysplasia ; biphenotypic leukemia . Age less equal 21 year time study entry . No prior therapy malignancy ( patient secondary AML follow treatment primary malignancy eligible ) except one dose intrathecal therapy . Negative pregnancy test Patient Down syndrome , acute promyelocytic leukemia ( APL ) , juvenile myelomonocytic leukemia ( JMML ) Positive pregnancy test Down syndrome , acute promyelocytic leukemia ( APL ) , juvenile myelomonocytic leukemia ( JMML )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Leukemia , Erythroblastic , Acute</keyword>
	<keyword>Erythroblastic Leukemia , Acute</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>Myeloid Leukemia , Acute</keyword>
</DOC>